Scpharmaceuticals INC

MannKind Corporation has completed its acquisition of scPharmaceuticals Inc. for $5.35 per share in cash plus a contingent value right, making scPharmaceuticals a wholly-owned subsidiary.

scPharmaceuticals Inc. obtained a $10.0 million unsecured promissory note from MannKind Corporation to support operations during their pending merger.

MannKind Corporation announced a definitive merger agreement to acquire scPharmaceuticals Inc. for an upfront cash payment of $5.35 per share plus contingent value rights up to $1.00 per share, expanding its presence in cardiometabolic medicine.

scPharmaceuticals Inc. secures an extension for its critical SmartDose drug delivery system supply agreement with West Pharmaceutical Services until December 31, 2027.

scPharmaceuticals Inc. announced strong second quarter 2025 financial results, driven by a 99% increase in FUROSCIX net revenue and significant growth in doses shipped.

scPharmaceuticals Inc. announced the successful election of three Class II Directors and the approval of its independent auditor and executive compensation at its Annual Meeting of Stockholders held on June 3, 2025.

SCPHARMACEUTICALS Inc. reported significant revenue growth for FUROSCIX in Q2 2025, driven by increased demand and expanded indications, despite continued operating losses.

scPharmaceuticals Inc. announces increased product revenue and the approval of FUROSCIX for treating edema in patients with chronic kidney disease in its Q1 2025 report.

scPharmaceuticals Inc. has filed an amendment to its quarterly report to disclose Rule 10b5-1 trading arrangements established by its CEO and CFO for tax withholding obligations related to vested stock units.

scPharmaceuticals Inc. reports a significant increase in product revenue for Q3 2024, alongside strategic financial moves and progress in its product pipeline.

scPharmaceuticals Inc. announced its second quarter 2024 financial results, highlighted by a significant increase in product revenue, a new $75 million term loan facility, a $50 million revenue participation agreement, and FDA approval to expand the FUROSCIX label to include NYHA Class IV heart failure patients.

scPharmaceuticals Inc. saw a significant increase in product revenue in the first quarter of 2024, driven by increased sales of its FUROSCIX product, despite ongoing operating losses.

scPharmaceuticals Inc. announces FDA approval for expanded FUROSCIX indication, positive financial results, and progress on autoinjector development.

scPharmaceuticals Inc.'s 2023 annual report highlights the commercial launch of FUROSCIX, positive FDA feedback on pipeline expansion, and financial results reflecting ongoing investment in growth.

scPharmaceuticals Director Frederick M. Hudson's stock options were converted to cash and CVRs following the company's merger with MannKind Corporation.

scPharmaceuticals CFO Rachael Nokes reported the disposition of common stock and stock options following the company's acquisition by MannKind Corporation.

scPharmaceuticals Inc. President and CEO John H. Tucker's equity holdings were converted into cash and contingent value rights following the merger with MannKind Corporation.

scPharmaceuticals Director Sara Bonstein's stock options were cancelled and converted into cash and Contingent Value Rights following the completion of a tender offer by MannKind Corporation.

Leonard D. Schaeffer, a director of scPharmaceuticals Inc., reported the disposition of all his common stock and stock options following the company's acquisition by MannKind Corporation.

scPharmaceuticals Director Klaus Veitinger's stock options were cancelled and converted to cash and CVRs following the completion of a tender offer by MannKind Corporation.

SCPharmaceuticals Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on June 3, 2025, with proxy materials available online.

scPharmaceuticals will hold its 2025 Annual Meeting of Stockholders online on June 3, 2025, to elect directors, ratify the appointment of its accounting firm, and approve executive compensation.

SCPharmaceuticals Inc. announces its 2024 Annual Meeting of Stockholders to be held on June 11, 2024, featuring proposals including the election of directors, ratification of the accounting firm, executive compensation approval, and an amendment to the certificate of incorporation.

scPharmaceuticals Inc. will hold its 2024 Annual Meeting of Stockholders online on June 11, 2024, to elect directors, ratify the appointment of an independent accounting firm, approve executive compensation, and approve an amendment to the certificate of incorporation.

Weiss Asset Management LP, WAM GP LLC, and Andrew M. Weiss report zero beneficial ownership in scPharmaceuticals Inc. common stock.

Laurence W. Lytton has filed an amendment to Schedule 13G, reporting zero beneficial ownership of scPharmaceuticals Inc. common stock.

Weiss Asset Management LP, along with WAM GP LLC and Andrew M. Weiss, has reported a 5.4% beneficial ownership stake in scPharmaceuticals Inc. common stock.

AIGH Capital Management LLC and Orin Hirschman have reported a complete divestment of their beneficial ownership in SCPHARMACEUTICALS INC., now holding 0% of common stock.

Tudor Investment Corporation and Paul T. Jones II have reported divesting their beneficial ownership in scPharmaceuticals Inc., reducing their stake to 0%.

Luther King Capital Management Corporation and J. Luther King, Jr. reported a 4.0% beneficial ownership in scPharmaceuticals Inc., holding 2,128,391 shares as of September 30, 2025.